Livagen — Research, Dosing & Price Guide

Livagen is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Professor Khavinson's research group in Russia, designed to normalize liver function and hepatocyte gene expression. It belongs to the Khavinson bioregulator class of peptides that act on chromatin structure to restore youthful gene expression patterns in specific organ systems.

Livagen interacts with heterochromatin regions in hepatocyte nuclei, causing localized chromatin decondensation that reactivates previously silenced genes. This epigenetic mechanism allows aged or damaged liver cells to resume production of proteins essential for detoxification, protein synthesis, and bile metabolism. Livagen has been shown to increase the transcriptional activity of ribosomal genes in hepatocytes, effectively restoring protein-synthetic capacity. It normalizes cytochrome P450 enzyme expression, improving Phase I detoxification, and upregulates glutathione-S-transferase for enhanced Phase II conjugation. Unlike pharmacological liver protectants, Livagen works at the gene expression level to restore the liver's intrinsic functional capacity.

• Khavinson et al. demonstrated Livagen causes chromatin decondensation in lymphocyte nuclei and hepatocytes, reactivating gene expression (Bulletin of Experimental Biology and Medicine, 2002)
• Studies showed Livagen normalized liver enzyme profiles (ALT, AST) in patients with chronic hepatitis after a 10-day course
• Research demonstrated increased ribosomal gene transcription in aged hepatocytes treated with Livagen
• Bioregulator peptide studies showed Livagen improved detoxification capacity and reduced oxidative stress markers in liver tissue
• Long-term studies (10+ years) of Khavinson bioregulators showed improved organ function and reduced age-related decline

• Standard oral protocol: 10–20 mg daily for 10–30 days
• Khavinson protocol: 10 mg oral, 2–3 times daily for 10–15 days, repeated every 3–6 months
• Sublingual: 5–10 mg dissolved under tongue twice daily for improved absorption
• Injectable (less common): 1–5 mg subcutaneous daily for 10 days
• Maintenance: 10 mg daily for 10 days every 3–6 months
• Often used as part of a bioregulator rotation protocol alongside other organ-specific peptides

Known Side Effects

• Generally very well-tolerated with minimal reported side effects
• Occasional mild GI discomfort (nausea, bloating) with oral dosing
• Rare: mild headache during first 2–3 days
• Injection site irritation if using injectable form
• No known serious adverse effects in published research

Safety Profile

Livagen has been studied as part of the Khavinson bioregulator program for over two decades. Bioregulator peptides are generally very safe due to their small size (tetrapeptides), natural amino acid composition, and physiological mechanism of action (gene expression normalization rather than pharmacological blockade). No toxicity has been demonstrated even at doses many times the therapeutic range. Contraindications: known hypersensitivity. Use with caution in individuals with autoimmune liver conditions. Safe for long-term intermittent use. No known drug interactions, but as it affects hepatic enzyme expression, monitor drug metabolism if taking narrow-therapeutic-index medications.

Days 1–5: No dramatic subjective changes. Gene expression normalization is occurring at the molecular level. Some users report subtle improvement in digestive comfort. Days 5–10: Improved sense of well-being. Those with elevated liver enzymes may see initial normalization on blood work. Better tolerance of dietary fats and alcohol (reflecting improved hepatic processing). Weeks 2–4 post-course: Full benefits manifest. Liver enzyme panels typically improve. Improved energy and detoxification capacity. Effects persist for months after a course due to the sustained nature of epigenetic changes. Subsequent courses (every 3–6 months) reinforce and build upon previous improvements.

Prices sourced from peptides.gg marketplace. Prices may vary.